Thank you for your interest in becoming a Clarity Study Investigator
Our Study Investigators play a pivotal role in Clarity’s efforts to advance innovation in science, assist healthcare professionals in providing a higher standard of care and, ultimately, improve the quality of life for patients worldwide.
To learn more, please call today to speak to a study representative or submit the form below.

OPTIMA-G
PAIN STUDY*
(Observing Pain Transdermal Treatments-Improving and Managing All GI Symptoms)
TAPER-P
PAIN STUDY*
(Treating Athletes in Pain: Evaluating Return to Play)
TARGET
SCAR & BURN STUDY*
(Topical Silicone in Restoring Scars and Burn Tissue: Evaluating Therapy)
TRIPLE-A
ALLERGY STUDY*
(Assisting and Accommodating Allergy Patients)
TREAT
ALLERGY STUDY*
(Transdermal Relief: Evaluating Allergy Topicals)VISIT STUDY PAGE
Areas of Research
We are currently conducting and developing clinical studies throughout the US in the following key areas:
Worldwide Recognition












Our studies continue to be recognized at leading national and international meetings. We have presented data at various conferences; winning first place for “Best Scientific Presentation/Data” at the American Professional Wound Care Association.
Peer reviewed articles related to our study data have been published and more are in final stages of submission.
Current Studies
TARGET Study
TARGET is a current, large-scale IRB-approved observational study on the effectiveness of topical/transdermal treatments for scar/burn characteristics, symptoms, and patient perceptions. It further evaluates the reduction of pain during the course of treatment.
Key Interim Results
69% of patients noticed reduction in scar size, results confirmed by clinician measurements, which showed a statistically significant reduction in the percentage of patients with largest (>20cm) scars from baseline (p<.003)
Over an average 128 days of scar/burn cream treatment use, patients reduced their usage of pain medications by 69% (p<.001)
Patients also reported reductions in itching (p<.001) and scar/burn interference with general activity, mood, sleep, life enjoyment, and an improvement in emotional well-being with the use of the treatment compound (p<.05)
Patients reported no serious adverse events and that the creams were safe and well-tolerated.
TREAT Study
TREAT is an IRB-approved observational study to evaluate patients’ experiences and/or perceptions of prescribed transdermal allergy medications to treat seasonal and perennial allergy symptoms.
OPTIMA-G Study
Clarity Science is conducting an IRB-approved observational study aimed at evaluating patients’ experiences and/or perceptions for those who have been prescribed a topical/transdermal pain medication. Pain and other symptoms will be evaluated by patient answers to validated assessment scales.
TAPER-P Study
Clarity Science is conducting an IRB- approved observational study aimed at evaluating efficacy and perceptions among non-elite and elite athletes with acute and chronic pain who have been treated with a topical analgesic.
Study
The TRIPLE-A study evaluates patients’ experiences and/or perceptions of premedications and preventative medications prescribed while undergoing Allergy Immunotherapy (Subcutaneous (SCIT) or Transdermal (TdIT)).
If you are a physician or healthcare provider interested in becoming a Study Investigator for any of our current or future studies, we would like to hear from you. Please complete our online Study Investigator Application or call our dedicated Healthcare Provider HelpDesk at
1-800-616-9403.
